Addario Lung Cancer Medical Institute

We fund and support investigator-led #lungcancer clinical trials.

[Addario Lung Cancer Medical Institute @ALCMI_research]

Oregon State University researchers have made a compelling dual-target discovery. They have developed a single therapy that simultaneously targets lung cancer and cancer cachexia. #lungcancer
https://t.co/oOWsee2nLm

[Addario Lung Cancer Medical Institute @ALCMI_research]

EGFR-mutated NSCLC is not just another subtype of lung cancer — it is a distinct molecular entity that demands a fundamentally different treatment strategy. #lungcancer
https://t.co/ld75VB73PJ

[Addario Lung Cancer Medical Institute @ALCMI_research]

Researchers at Roswell Park Comprehensive Cancer Center and Winship Cancer Institute of Emory University have developed an AI-powered tool that can predict treatment response in ES-SCLC before a single dose of chemotherapy is given. #lungcancer
https://t.co/1Ws348rcrF

[Addario Lung Cancer Medical Institute @ALCMI_research]

New research is challenging the idea of how old is too old for surgery in early-stage lung cancer. #lungcancer
https://t.co/yMYQMIhpjs

[Addario Lung Cancer Medical Institute @ALCMI_research]

Congrats to the researchers at the ALCMI consortium member, Mass General Brigham Cancer Institute. They have shown that pralsetinib can extend median overall survival for advanced RET fusion-positive NSCLC from roughly 4–11 months to 44 months. #lungcancer
https://t.co/44kzU6vGnM

[Addario Lung Cancer Medical Institute @ALCMI_research]

Congrats to TRIANA Biomedicines! The company has earned FDA Fast Track designation for TRI-611, a first-in-class molecular glue degrader targeting ALK fusion proteins in ALK-positive non-small cell lung cancer. #lungcancer
https://t.co/dTK0ZpTlQS

[Addario Lung Cancer Medical Institute @ALCMI_research]

New trial alert! Memorial Sloan Kettering Cancer Center has launched a new investigator-initiated Phase 2 trial evaluating BIO 300 Oral Suspension in patients with non-small cell lung cancer and concomitant interstitial lung disease. #lungcancer
https://t.co/b0GFTRZfCr

[Addario Lung Cancer Medical Institute @ALCMI_research]

A new study found that incidental findings flagged during low-dose CT screening could be signs of other non-lung, undiagnosed cancers. #lungcancer
https://t.co/ZztRBUN8yG

[Addario Lung Cancer Medical Institute @ALCMI_research]

Congratulations to Anurag Singh, MD, and the team at Roswell Park Comprehensive Cancer Center on a finding that could reshape how we treat early-stage non-small cell lung cancer. #lungcancer
https://t.co/v0zg3wyhz2

[Addario Lung Cancer Medical Institute @ALCMI_research]

Dr. Lovly and Dr. Lee examined how risk-benefit profiles should drive frontline treatment selection, weighing efficacy, toxicity, and patient-specific factors when choosing between osimertinib monotherapy and combination approaches. #lungcancer
https://t.co/dHmRiwOPEK

[Addario Lung Cancer Medical Institute @ALCMI_research]

Updated data from the phase 2 PALOMA-2 trial point to a meaningful advance in first-line treatment for patients with EGFR-mutated metastatic NSCLC. #lungcancer
https://t.co/6BFTAynexo

[Addario Lung Cancer Medical Institute @ALCMI_research]

Fascinating! Researchers have identified that lung cells age at different rates, with implications for lung cancer risk and targeted therapies. #lungcancer
https://t.co/ioSBORorbP

[Addario Lung Cancer Medical Institute @ALCMI_research]

New research into treatment resistance! Researchers at Johns Hopkins Medicine have identified a promising new therapeutic target that could overcome one of the most stubborn challenges in small cell lung cancer treatment. #lungcancer
https://t.co/zwty35tv1Y

[Addario Lung Cancer Medical Institute @ALCMI_research]

Researchers at VCU Massey Comprehensive Cancer Center have uncovered a critical vulnerability in p53-mutant lung tumors, and it could reshape how we treat a majority of patients. #lungcancer
https://t.co/cqMrThI1uk

[Addario Lung Cancer Medical Institute @ALCMI_research]

We'll be keeping tabs on this one. bioAffinity Technologies has launched a landmark 2,000-patient longitudinal study that could redefine how we approach early lung cancer detection. #lungcancer
https://t.co/nI05gl0Li5

[Addario Lung Cancer Medical Institute @ALCMI_research]

Researchers at Dartmouth College and Baylor University have identified a DNA methylation signature that distinguishes the two major subtypes of non-small cell lung cancer and predicts early survival in smokers with lung squamous cell carcinoma. #lungcancer
https://t.co/JVIYE5Ix41

[Addario Lung Cancer Medical Institute @ALCMI_research]

Medicaid expansion under the Affordable Care Act is saving lives, and a landmark study of more than 514,000 NSCLC patients now quantifies exactly how much. #lungcancer
https://t.co/yyZt5zJwIQ

[Addario Lung Cancer Medical Institute @ALCMI_research]

Researchers at Novant Health have found that delaying immunotherapy initiation in extensive-stage small cell lung cancer does not compromise survival outcomes. #lungcancer
https://t.co/YrOg0fQLCJ

[Addario Lung Cancer Medical Institute @ALCMI_research]

Researchers at the University of Gothenburg have uncovered a key molecular driver of lung cancer metastasis in older patients. #lungcancer
https://t.co/QkXRQb9G2z

[Addario Lung Cancer Medical Institute @ALCMI_research]

Whoa! This is big. Researchers at UVA Health have identified a direct link between severe respiratory viral infections and increased lung cancer risk. #lungcancer
https://t.co/ehykpiqfQZ